Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

FOLD

Amicus Therapeutics Inc

Nov 25 • 04:00PM ET

9.87

-0.02 -0.20 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX SRPT BMRN REGN CRSP EDIT PFE QURE AGIO BLUE

| Held by: VTI IWM VB XBI VBK VXF IWO IBB SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.04	Insider Own	2.02%	Shs Outstand	308.50M	Perf Week	2.92%
Market Cap	3.05B	Forward P/E	36.75	EPS next Y	0.27	Insider Trans	-0.41%	Shs Float	302.30M	Perf Month	11.15%
Enterprise Value	3.22B	PEG	-	EPS next Q	0.07	Inst Own	101.91%	Short Float	5.64%	Perf Quarter	29.19%
Income	-14.06M	P/S	5.09	EPS this Y	89.68%	Inst Trans	-1.23%	Short Ratio	3.32	Perf Half Y	61.80%
Sales	598.70M	P/B	13.21	EPS next Y	1546.18%	ROA	-1.70%	Short Interest	17.05M	Perf YTD	4.78%
Book/sh	0.75	P/C	11.54	EPS next 5Y	-	ROE	-6.87%	52W High	10.57 -6.62%	Perf Year	3.89%
Cash/sh	0.86	P/FCF	314.27	EPS past 3/5Y	41.55% 34.10%	ROIC	-2.12%	52W Low	5.51 79.13%	Perf 3Y	-9.45%
Dividend Est.	-	EV/EBITDA	76.55	Sales past 3/5Y	20.03% 23.72%	Gross Margin	88.50%	Volatility	5.49% 4.52%	Perf 5Y	-55.74%
Dividend TTM	-	EV/Sales	5.39	EPS Y/Y TTM	87.30%	Oper. Margin	5.77%	ATR (14)	0.40	Perf 10Y	4.56%
Dividend Ex-Date	-	Quick Ratio	2.09	Sales Y/Y TTM	21.28%	Profit Margin	-2.35%	RSI (14)	68.74	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	2.99	EPS Q/Q	352.49%	SMA20	6.27%	Beta	0.44	Target Price	15.90
Payout	-	Debt/Eq	1.92	Sales Q/Q	19.46%	SMA50	13.60%	Rel Volume	0.79	Prev Close	9.89
Employees	499	LT Debt/Eq	1.88	Earnings	Nov 04 BMO	SMA200	30.22%	Avg Volume	5.13M	Price	9.87
IPO	May 31, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	55.44% 2.02%	Trades		Volume	4,042,253	Change	-0.20%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-18-25	Upgrade	Needham	Hold → Buy	$14
Jul-17-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$108
Dec-13-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$17 → $12
Sep-06-24	Initiated	Jefferies	Buy	$18
May-30-24	Initiated	Wells Fargo	Overweight	$18
May-14-24	Upgrade	Guggenheim	Neutral → Buy	$13
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$15 → $20
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$14
Apr-13-22	Resumed	Goldman	Neutral	$11
Jan-14-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$12 → $16
Nov-15-21	Upgrade	Stifel	Hold → Buy	$12 → $16
Sep-30-21	Upgrade	JP Morgan	Neutral → Overweight	$16
Jul-19-21	Resumed	BTIG Research	Buy	$15
May-27-21	Initiated	Needham	Hold
May-21-21	Initiated	UBS	Buy	$16
Apr-14-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$17
Mar-02-21	Initiated	Stifel	Hold	$13
Feb-12-21	Downgrade	JP Morgan	Overweight → Neutral	$19
Feb-12-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$30 → $17
Dec-28-20	Resumed	Cantor Fitzgerald	Overweight	$20 → $30

Show Previous Ratings

Today 02:00PM	FDA Greenlights Novartis' Gene Replacement Treatment for SMA (Zacks)
Nov-24-25 01:53PM	BAYRYs Cardiovascular Drug Hits Goals in Late-Stage Study (Zacks)
Nov-21-25 10:15AM	NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth (Zacks)
Nov-19-25 08:53AM	BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU (Zacks)
Nov-14-25 08:11AM	GILD's Investigational Regimen for HIV Treatment Meets Primary Goal (Zacks)
01:46PM	Loading…
Nov-13-25 01:46PM	Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth? (Zacks)
Nov-11-25 12:52PM	Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus (Zacks)
Nov-10-25 08:16PM	Goldman Sachs Bullish on Amicus Therapeutics (FOLD) Following Q3 2025 Results (Insider Monkey)
09:55AM	Wall Street Analysts Believe Amicus Therapeutics (FOLD) Could Rally 76.32%: Here's is How to Trade (Zacks)
01:44AM	Zacks.com featured highlights include EverQuote, Amicus, Lam Research and Cboe Global Markets EverQuote, Amicus, Lam Research and Cboe Global Markets (Zacks)
Nov-07-25 10:40AM	Bet on These 4 Top-Performing Liquid Stocks to Maximize Returns (Zacks)
Nov-06-25 10:43AM	Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
10:24AM	Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance (Zacks)
09:24AM	RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y (Zacks)
08:27AM	ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales (Zacks)
10:52AM	Loading…
Nov-05-25 10:52AM	EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales (Zacks)
10:48AM	Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y (Zacks)
10:41AM	Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up (Zacks)
10:30AM	Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles (Zacks)
10:08AM	Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues (Zacks)
09:30AM	Compared to Estimates, Amicus Therapeutics (FOLD) Q3 Earnings: A Look at Key Metrics (Zacks)
Nov-04-25 04:07PM	Amicus Therapeutics Inc (FOLD) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
11:43AM	ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down (Zacks)
09:54AM	Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
08:35AM	Amicus Therapeutics (FOLD) Beats Q3 Earnings and Revenue Estimates (Zacks)
07:29AM	Amicus Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
Oct-31-25 01:45PM	Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates (Zacks)
10:37AM	ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales (Zacks)
07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025 (GlobeNewswire)
10:28AM	Loading…
Oct-30-25 10:28AM	BHC Stock Up on Q3 Earnings Beat, Salix and Solta Drive Sales (Zacks)
Oct-23-25 07:00AM	Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025 (GlobeNewswire)
Oct-14-25 08:23AM	FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months (Zacks)
Oct-08-25 11:23AM	Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease (Zacks)
12:57AM	What Does Wall Street Think About Amicus Therapeutics (FOLD)? (Insider Monkey)
Oct-07-25 12:00PM	All You Need to Know About Amicus Therapeutics (FOLD) Rating Upgrade to Strong Buy (Zacks)
11:32AM	SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal (Zacks)
08:34AM	Zacks.com featured highlights include Amicus Therapeutics, Micron Technology and General Dynamics (Zacks)
Oct-06-25 09:22AM	Bet on These 3 Stocks With Upgraded Broker Ratings for Solid Returns (Zacks)
Oct-02-25 09:40AM	Can Galafold Drive Amicus' Growth Through the Rest of 2025? (Zacks) +7.00%
Sep-25-25 11:26AM	RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential? (Zacks)
09:28AM	Atara Biotherapeutics (ATRA) Soars 10.0%: Is Further Upside Left in the Stock? (Zacks)
Sep-19-25 09:31AM	Strength Seen in Amicus Therapeutics (FOLD): Can Its 6.4% Jump Turn into More Strength? (Zacks)
Sep-18-25 09:38AM	Target initiated, Nike upgraded: Wall Street's top analyst calls (The Fly) +6.40%
Sep-08-25 09:00AM	New 4-Year Data for Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) Presented at ICIEM (GlobeNewswire)
Aug-29-25 07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025 (GlobeNewswire)
05:08AM	Amicus Therapeutics, Inc. (FOLD) Expands Pipeline With Rare Kidney Disease Drug (Insider Monkey)
Aug-06-25 08:30AM	Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators (PR Newswire)
Aug-05-25 12:20PM	Earnings Estimates Moving Higher for Amicus Therapeutics (FOLD): Time to Buy? (Zacks)
09:55AM	Does Amicus Therapeutics (FOLD) Have the Potential to Rally 138.21% as Wall Street Analysts Expect? (Zacks)
Aug-03-25 05:00PM	Amicus Therapeutics Inc (FOLD) Q2 2025 Earnings Call Highlights: Sustained Revenue Growth ... (GuruFocus.com)
Aug-01-25 11:49AM	FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales (Zacks) +5.51%
Jul-31-25 08:15AM	Amicus Therapeutics (FOLD) Misses Q2 Earnings Estimates (Zacks)
07:11AM	Amicus Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
Jul-25-25 10:00AM	Moderna (MRNA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-24-25 11:47PM	Morgan Stanley Upgrades Amicus (FOLD) on IP Strength and Pipeline Expansion (Insider Monkey)
10:00AM	Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-21-25 07:00AM	Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025 (GlobeNewswire)
Jul-18-25 06:57AM	Fabry Disease Treatment Analysis Report 2025 \| Market to Reach $3.86 Billion by 2030, Rising Fabry Disease Prevalence and Demand for Targeted Therapies Drive Growth (GlobeNewswire) -5.25%
Jul-17-25 09:46AM	Starbucks downgraded, Oracle initiated: Wall Street's top analyst calls (The Fly)
Jul-16-25 12:23PM	Amicus (FOLD) Gets Japan Approval for Pombiliti + Opfolda (Insider Monkey)
Jul-11-25 11:27AM	TD Cowen Remains Bullish on Amicus Therapeutics (FOLD) With a $20 PT (Insider Monkey)
Jul-06-25 04:15AM	Amicus Therapeutics (FOLD) Announces Approval for Pombiliti + Opfolda by Japan's Ministry of Health, Labour and Welfare (MHLW) (Insider Monkey)
Jun-25-25 07:00AM	Amicus Therapeutics Announces Approval of Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) in Japan (GlobeNewswire)
Jun-24-25 12:45PM	Amicus Therapeutics Publishes Positive PROPEL Study Data for Pompe Disease Treatment (Insider Monkey)
Jun-03-25 07:45AM	New Strong Sell Stocks for June 3rd (Zacks)
07:00AM	New Analysis of Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat) Published in Muscle and Nerve (GlobeNewswire)
May-30-25 07:00AM	Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 (GlobeNewswire)
May-13-25 08:51AM	Is Amicus Therapeutics (FOLD) the Best Low Priced Biotech Stock to Buy Now? (Insider Monkey)
May-07-25 07:00AM	Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference (GlobeNewswire)
May-02-25 01:18PM	FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls (Zacks)
May-01-25 04:24PM	Amicus Therapeutics, Inc. (FOLD) Q1 2025 Earnings Call Transcript (Seeking Alpha) -13.02%
10:44AM	Dimerix and Amicus to commercialise DMX-200 in US (Pharmaceutical Technology)
09:48AM	Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
08:15AM	Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates (Zacks)
07:17AM	Amicus Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
Apr-30-25 07:12PM	Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States (GlobeNewswire)
Apr-29-25 10:01AM	Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline (Zacks)
Apr-24-25 10:01AM	Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Apr-23-25 12:57PM	Is Amicus Therapeutics, Inc. (FOLD) Among the Best Guru Stocks to Buy According to Wall Street Analysts? (Insider Monkey)
09:25AM	Amicus Therapeutics to Report Q1 Earnings: What's in the Cards? (Zacks)
Apr-21-25 07:00AM	Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025 (GlobeNewswire)
Apr-17-25 08:21AM	4 Healthcare Stocks to Buy as the Sector Faces Government Heat (Zacks)
Apr-15-25 08:17AM	BMY Down on Heart Drug Camzyos Failure in Late-Stage Study (Zacks)
Apr-11-25 01:18PM	Bayer Obtains Full FDA Approval for Oncology Drug Vitrakvi (Zacks)
08:21AM	Is ??Amicus Therapeutics, Inc. (FOLD) the Best Low Priced Growth Stock To Invest In? (Insider Monkey)
Apr-09-25 01:44PM	BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo (Zacks)
10:58AM	RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks (Zacks)
Apr-08-25 10:06AM	Is Amicus Therapeutics, Inc. (FOLD) the Best Low Cost Stock to Buy According to Billionaires? (Insider Monkey) -6.01%
Apr-07-25 01:22PM	5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025 (Zacks)
Apr-02-25 01:38PM	GRI Stock Down on Public Offering Despite Encouraging IPF Study Data (Zacks)
Apr-01-25 03:00PM	CHMP Issues Positive Opinion for Label Expansion of BMY's Opdivo (Zacks)
10:50AM	CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal (Zacks)
06:55AM	New Strong Buy Stocks for April 1st (Zacks)
Mar-28-25 12:00PM	abrdn Focused U.S. Small Cap Active ETF Q4 2024 Commentary (Seeking Alpha)
Mar-21-25 11:30AM	Amicus Therapeutics (FOLD) Up 0.1% Since Last Earnings Report: Can It Continue? (Zacks)
10:10AM	Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio (Zacks)
Mar-17-25 03:37PM	Is Amicus Therapeutics Inc. (FOLD) the Best Nasdaq Stock Under $20 to Buy Now? (Insider Monkey)

Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ELLEN ROSENBERG	Officer	Nov 25 '25	Proposed Sale	9.89	36,000	356,040		Nov 25 04:27 PM
JEFFREY CASTELLI	Officer	Nov 24 '25	Proposed Sale	9.56	76,158	728,070		Nov 24 04:25 PM
DAVID CLARK	Officer	Nov 24 '25	Proposed Sale	9.56	25,643	245,147		Nov 24 04:24 PM
BRADLEY CAMPBELL	Director	Nov 24 '25	Proposed Sale	9.56	14,587	139,452		Nov 24 04:24 PM
ELLEN ROSENBERG	Officer	Nov 24 '25	Proposed Sale	9.56	36,000	344,160		Nov 24 04:23 PM
Clark David Michael	Chief People Officer	Nov 04 '25	Sale	9.51	25,643	243,860	322,618	Nov 05 04:05 PM
DAVID CLARK	Officer	Nov 04 '25	Proposed Sale	8.86	25,643	227,197		Nov 04 04:33 PM
Campbell Bradley L	President and CEO	Feb 19 '25	Option Exercise	9.03	400	3,612	1,151,057	Feb 21 07:27 PM
Campbell Bradley L	President and CEO	Feb 19 '25	Sale	10.00	400	4,000	1,150,657	Feb 21 07:27 PM
BRADLEY CAMPBELL	Director	Feb 19 '25	Proposed Sale	9.85	400	3,940		Feb 19 04:36 PM
Campbell Bradley L	President and CEO	Dec 02 '24	Option Exercise	8.61	7,500	64,575	894,154	Dec 03 06:12 PM
Campbell Bradley L	President and CEO	Dec 02 '24	Sale	10.02	7,500	75,124	886,654	Dec 03 06:12 PM
BRADLEY CAMPBELL	Director	Dec 02 '24	Proposed Sale	9.98	7,500	74,850		Dec 02 04:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

FOLD

Amicus Therapeutics Inc

Upgrade your FINVIZ experience